Adenosine receptors (ARs) function in the body’s response to conditions of pathology and
stress associated with a functional imbalance, such as in the supply and demand of energy/…

The A 3 adenosine receptor (A 3 AR) subtype is a novel, promising therapeutic target for
inflammatory diseases, such as rheumatoid arthritis (RA) and psoriasis, as well as liver cancer. …

Blockchain has recently attracted tremendous interest due to its ability to enhance security
and privacy through a immutable shared distributed ledger. Blockchain's ability to detect …

The blockchain technology has emerged as an attractive solution to address performance
and security issues in distributed systems. Blockchain's public and distributed peer-to-peer …

Major depressive disorder is among the most commonly diagnosed disabling mental
diseases. Several non-pharmacological treatments of depression upregulate adenosine …

Chronic pain is a global burden that promotes disability and unnecessary suffering. To date,
efficacious treatment of chronic pain has not been achieved. Thus, new therapeutic targets …

Many commonly used chemotherapeutics including oxaliplatin are associated with the
development of a painful chemotherapy-induced peripheral neuropathy (CIPN). This dose-…

Clinical management of chronic neuropathic pain is limited by marginal effectiveness and
unacceptable side effects of current drugs. We demonstrate A 3 adenosine receptor (A 3 AR) …

A 3 AR agonists prevent paclitaxel-induced neuropathic pain via modulating spinal redox-dependent
signaling pathways (restoring glutamatergic homeostasis, attenuating …

The A 3 adenosine receptor (A 3 AR) has emerged as a therapeutic target with A 3 AR
agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of …